Xermelo (Telotristat Etiprate) Patent Expiration, LOE Window & CMS Spending
Xermelo (Telotristat Etiprate) by Tersera Therapeutics: FDA Orange Book core substance LOE 2031-02-28, 0 AB generics, $24.2M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Tersera Therapeutics |
| FDA Application & Pathway | N208794 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-02-28 |
| Last Listed Patent or Exclusivity Date | 2031-02-28 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $24.2M |
| 2024 Medicare Part D Spend | $24.2M |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 48.9% 2-yr change) |